Colorectal Cancer Screening Market, By Screening Tests (Stool-based Tests, Colonoscopy, CT Colonography , Flexible Sigmoidoscopy, Others), By End User (Hospitals, Specialty Clinics, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : May 2024

Code : CMI5098

Pages :181

Formats :

Excel and PDF

Industry : Clinical Diagnostic

Key Developments

On May 6, 2024, Geneoscopy, Inc., a life sciences company, announced that the U.S. Food and Drug Administration had approved its noninvasive colorectal cancer screening test- ColoSense. ColoSense is indicated as a screening test for adults, 45 years of age or older, who are at typical average risk for developing CRC.
On April 10, 2024, UC Davis Health, a health center in the U.S., launched a digital health program for colorectal cancer screening that uses the Cologuard test. Cologuard is a non-invasive, stool DNA-based test that detects not only blood in stool but 11 distinct biomarkers are used to identify colorectal cancer and precancerous polyps.
In November 2023, Guardant Health, Inc., a healthcare company, launched its blood-based colorectal cancer screening test- Shield, in collaboration with Samsung Medical Center in South Korea
In February 2021, The European Union set out a USD 4,313.44 Mn (€4 Bn) Beating Cancer plan, including the most concerted push ever for research and its translation through to better treatments. The plan will fund technology development, improve access to therapies, create new research networks, promote disease prevention, and offer better support for people who survive cancer.